Match Day brings physician residents to St. Rita's
Twelve residents are in Internal Medicine, six in Emergency Medicine, six in Family Medicine, and two are in Podiatric Medicine & Surgery.
This year's fellow is the first in the new Healthcare Administration Leadership Management Fellowship, which equips physicians with leadership skills for the healthcare environment.
Match Day showcases where medical students will begin their residency training.
"Match Day is a moment of great pride — not just for our incoming residents, but for all of us at Mercy Health-St. Rita's," Mercy Health-Lima Chief Clinical Officer Dr. Matt Owens said.
This year's class comes from 18 different medical schools, according to the press release.
For more information on residency and fellowship programs, visit www.mercy.com/residency.
Featured Local Savings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Harvard Business Review
4 hours ago
- Harvard Business Review
AI in Life Sciences
Download the Report The life sciences industry needs a shot of adrenaline. An aging population and a rise in chronic diseases are fueling the demand for highly accurate medical imaging and diagnostic tools. Pharmaceutical companies and manufacturers are under growing pressure to keep pace with supply and demand for critical medications and medical devices, respectively. Patients, meanwhile, are increasingly demanding personalized health care experiences that cater to their unique needs.
Yahoo
7 hours ago
- Yahoo
Mom Thought She Just Had Dry Skin. Months Later, She Had Hole 'The Size of a Quarter' in Her Nose After Skin Cancer Diagnosis
Amanda Anderson, 43, received the diagnosis in June after first noticing a "small irritated spot" on her nose in January NEED TO KNOW Amanda Anderson, a mother of four, discovered a small spot on her nose that she thought was dry skin But after several appointments, doctors determined it was actually basal cell carcinoma She underwent surgery to remove the spot and documented her journey online A mother of four thought she just had a bit of dry skin on her nose, months before receiving a shocking diagnosis. Amanda Anderson, 43, from Layton, Utah, first noticed she had a small spot on the side of her nose in January of this year; however, she wasn't initially concerned, as she said her skin often gets dry during the winter months, per SWNS. Anderson ended up getting the spot checked out just to be on the safe side and was given a cream. When the spot came back and started to bleed and scab, Anderson booked another appointment with the doctor, only to be told she didn't have anything to worry about. After having a gut feeling that something was wrong, Anderson went to another medic, who then booked her in for a biopsy in June, before the results came back as basal cell carcinoma on June 23. She was scheduled for surgery three days later to remove the spot. Per the Mayo Clinic, "Basal cell carcinoma is a type of skin cancer. Basal cell carcinoma begins in the basal cells — a type of cell within the skin that produces new skin cells as old ones die off." "Basal cell carcinoma often appears as a slightly transparent bump on the skin, though it can take other forms. Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as your head and neck," the site adds. Anderson has documented her skin cancer journey on TikTok, writing in the caption of one of her videos, "WEAR YOUR SUNSCREEN!!" "I had a small irritated spot on my nose for 6 months. I finally went into the dermatologist. It wasn't a huge shock to find out it was Basal Cell Carcinoma," she added. "Getting it removed was a HUGE shock. I had no idea what I was getting into!" Anderson wrote, sharing in the clip that she'd had Mohs surgery, and that medics ended up having to do three passes. She wrote over the video per the AP, "It was sooo much bigger than I was expecting," confirming she had 50 plus stitches. The clip featured multiple images showing Anderson's cancer journey, including her having a hole cut from her nose to remove all the cancer cells. The Mayo Clinic describes Mohs surgery as "a procedure used to treat skin cancer," adding, "This surgery involves cutting away thin layers of skin. Each thin layer is looked at closely for signs of cancer. The process keeps going until there are no signs of cancer." "The goal of Mohs surgery is to remove all of the skin cancer without hurting the healthy skin around it. Mohs surgery allows the surgeon to be sure that all the cancer is gone. This makes it more likely that the cancer is cured. It reduces the need for other treatments or more surgery," the site states. Anderson recalled of her initial symptoms, "It was just a little dry spot on the side of my nose," adding, "With it being the winter it's common to have dry patches. I wasn't super concerned at the beginning," per SWNS. Anderson — whose father, Kirk Romney, 66, has also had skin cancer, and has had over 17 Mohs surgeries to remove cancerous cells from his face, neck and shoulders — insisted, "When I noticed the spot at first I wasn't too concerned." "It's typical to get dry patches because of the weather here in Utah," she added. Anderson said of receiving the skin cancer diagnosis, "It's hard to hear. It's on my face and as a woman we do everything we can to make sure our faces look as good as possible." "I'm obsessed about sun cream and shade - I have been my whole life," she added. "So it was a bit of a gut punch." Anderson added of doctors removing part of her nose to get the cancer out, "It was about the size of a quarter. They cut above and below the hole and fold the skin over." Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Anderson, who continues to keep her followers updated regarding her skin cancer journey on TikTok, confirmed she won't need further treatment, but will have to have check-ups every six months. She said of now wanting to warn others, "The damage is done when you're young. I encourage my daughters to put sun cream on underneath their makeup." "I'm trying to build healthy habits in my kids," Anderson added. "People don't realize you can get sunburnt through the window of a car. We have to take care of our skin like you would your teeth. Skin cancer is so preventable." PEOPLE has reached out to Anderson for an update on her recovery. Read the original article on People Solve the daily Crossword
Yahoo
11 hours ago
- Yahoo
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
SHENZHEN, CHINA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- On 18 August, China Medical System Holdings Limited ('CMS' or the 'Company') announced its interim results for the six months ended 30 June 2025 (the 'Reporting Period'), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement ('National VBP'), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company's key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company's exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its 'New CMS' blueprint since 2018, anchored on the three strategic pillars of 'product innovation, commercial model reform, and international expansion' to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company's strategic upgrade has been gradually translated into tangible achievements. 'New Products' Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company's three strategic pillars, the 'product innovation' strategy leverages a three-dimensional innovation mechanism of 'overseas licensing, domestic collaboration, and in-house R&D' to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer's disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company's diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing 'New Models' and 'New Markets' Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its 'New Models — Commercial Model Reform' strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its 'New Markets - International Expansion' strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both 'in-hospital + out-of-hospital' and 'online + offline' channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the 'coverage of dermatology indications' and the 'revenue scale of dermatological prescription drugs', and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its 'industrial internationalization' strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of 'R&D–Manufacturing–Commercialization' for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore's HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of 'New CMS' is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media Contact Brand: China Medical System Holdings Ltd. Contact: CMS Investor Relations Email: ir@ Website: Source: China Medical System Holdings in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
